After announcing last week a co-marketing pact with PerkinElmer in the cell analysis field, Invitrogen CEO Greg Lucier told attendees of the UBS Global Life Sciences conference in New York this week that they should expect the company to make further moves to build its presence in that market.

For PerkinElmer, the deal could help it gain better overall name recognition in cell-based screening, which could help its LumiLux platform gain market penetration more rapidly.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.